Try our Advanced Search for more refined results

Juno Therapeutics, Inc. et al v. Kite Pharma, Inc.

  1. April 08, 2020

    Juno Awarded Over $1.1B In Final Judgment For IP Case

    A California federal judge on Wednesday entered final judgment awarding Juno Therapeutics and Sloan Kettering enhanced damages of over $389 million while boosting the total award to over $1.1 billion after a jury found that Kite Pharma willfully infringed a patent for a cancer immunotherapy.

  2. January 22, 2020

    Bristol-Myers Wants $1.5B From Gilead After Cancer IP Trial

    A Bristol-Myers Squibb subsidiary and Memorial Sloan Kettering Cancer Center have asked a California federal judge to more than double a jury's $752 million patent infringement verdict against a Gilead unit for its cancer treatment Yescarta, saying the company must be punished for its "undisputed willfulness."

  3. December 13, 2019

    Jury Says Kite Pharma Owes $752M For Infringing Patent

    A California federal jury awarded Juno Therapeutics and Sloan Kettering $752 million on Friday after finding that Kite Pharma willfully infringed a patent for cancer immunotherapy, bringing a dramatic end to a high-stakes trial that hinged largely on a purported typo.

  4. December 12, 2019

    Jury Told Juno's Bid For $752M Patent Damages 'Just Crazy'

    Juno Therapeutics and Sloan Kettering's bid for $752 million in damages over Kite Pharma's alleged infringement of a cancer immunotherapy patent is "just crazy," Kite's attorney told a California federal jury during closing arguments Thursday, noting the drug at issue has only logged $604 million in sales.

  5. December 11, 2019

    Jury Told Patent Typo Shouldn't Get Kite Off $752M Hook

    Kite Pharma shouldn't be allowed to "exploit" a simple typo to "kill" a valuable cancer patent, a lawyer for Juno Therapeutics and Sloan Kettering told a California jury during closings Wednesday, arguing that Kite infringed the patent and owes $752 million in damages.

  6. December 10, 2019

    Ex-Kite CEO Undermines Testimony Of Pharma Co.'s Founder

    Contradicting testimony from Kite Pharma founder Arie Belldegrun, the company's former CEO conceded under questioning in a California federal trial Tuesday that a meeting Belldegrun had with a Sloan Kettering executive was about potentially licensing a cancer immunotherapy patent it's now accused of infringing.

  7. December 09, 2019

    Juno's Expert Pegs Patent License Value At $752M In Kite Trial

    An economist hired by Sloan Kettering and Juno Therapeutics told a California jury Monday that defendant Kite Pharma would have paid $752 million to license the cancer immunotherapy patent it's accused of infringing, saying that estimate is large but "conservative."

  8. December 05, 2019

    Jury Told Kite Wanted Sloan Kettering's Patients, Not Patent

    The founder of Kite Pharma on Thursday countered claims that he sought to license a Sloan Kettering-developed patent that Kite is accused of infringing, testifying to a California federal jury that he only pursued a meeting with a Sloan Kettering researcher to "get access to his patients," not his patent.

  9. December 04, 2019

    Jury Told 'Whole Field' Knows Kite Infringed Juno's Patent

    A co-inventor of a cancer immunotherapy treatment licensed by Juno Therapeutics told a California jury on Wednesday that he never imagined that answering a phone call from a "towering figure" in his field would come back to bite him and result in Kite Pharma infringing his patent.

  10. December 03, 2019

    Possible Patent Typo Debated As Juno, Kite IP Trial Kicks Off

    Lawyers for Juno Therapeutics and Kite Pharma delivered opening statements Tuesday in Juno's infringement suit over its groundbreaking cancer immunotherapy — a potentially multibillion-dollar fight that may turn on whether a California federal jury believes Juno's patent contained a simple typo or not.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!